Core Viewpoint - Heng Rui Medicine (恒瑞医药) reported a significant increase in revenue and net profit for the first three quarters of 2025, alongside the approval of a new diabetes treatment, marking a notable innovation in the field [1] Financial Performance - The company achieved an operating revenue of 23.188 billion yuan, representing a year-on-year increase of 14.85% [1] - The net profit attributable to shareholders reached 5.751 billion yuan, reflecting a year-on-year increase of 24.5% [1] - Basic earnings per share were reported at 0.89 yuan [1] Product Development - Heng Rui Medicine's subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for its self-developed drug, Henggeli Jing Regaglitin Metformin Sustained-Release Tablets (瑞乐唐) [1] - This product is designed to improve blood sugar control in adults with type 2 diabetes who have inadequate control with metformin [1] - 瑞乐唐 is noted as the first domestically developed oral triple combination therapy for diabetes in China, indicating a significant breakthrough in diabetes treatment innovation [1]